TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 43,744.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,226 shares of the company's stock after purchasing an additional 104,986 shares during the period. GAMMA Investing LLC owned about 0.31% of TransMedics Group worth $7,080,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Arizona State Retirement System raised its stake in shares of TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after buying an additional 184 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after purchasing an additional 317 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $31,000. Alliancebernstein L.P. increased its stake in shares of TransMedics Group by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after purchasing an additional 500 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of TransMedics Group by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company's stock worth $86,000 after purchasing an additional 504 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 3rd. Piper Sandler restated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and a consensus target price of $125.11.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider now owns 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director now directly owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,418 shares of company stock valued at $1,512,613 in the last ninety days. Company insiders own 7.00% of the company's stock.

TransMedics Group Trading Up 0.1%

Shares of NASDAQ TMDX traded up $0.16 on Thursday, reaching $143.04. 495,293 shares of the company traded hands, compared to its average volume of 1,357,759. The stock has a market capitalization of $4.84 billion, a PE ratio of 152.17 and a beta of 2.10. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a 50 day moving average of $105.77 and a 200 day moving average of $81.57.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same period in the previous year, the firm earned $0.35 earnings per share. TransMedics Group's revenue was up 48.2% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.